PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Woo, Jacky ^a,c   Vierboom, Michel P M ^b   Kwon, Hakju ^a   Chao, Debra ^a   Ye, Shiming ^a   Li, Jianmin ^a   Lin, Karen ^a   Tang, Irene ^a   Belmar, Nicole A ^a   Hartman, Taymar ^a   Breedveld, Elia ^b   Vexler, Vladimir ^a,d   't Hart, Bert A ^b   Law, Debbie A ^a,e   Starling, Gary C ^a,e  

^a ABBVIE INC   (United States)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c Gilead   (United States)

^d Coherus Biosciences ^*  (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD20 ANTIGEN; CD319 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PDL 241; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN; IMMUNOGLOBULIN RECEPTOR; SLAMF7 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; B LYMPHOCYTE; BONE REMODELING; CELL POPULATION; CONTROLLED STUDY; DEPLETION; EXPERIMENTAL ARTHRITIS; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; JOINT SWELLING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; RHEUMATOID ARTHRITIS; SYNOVIUM; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; RHESUS MONKEY; SCID MOUSE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; MACACA MULATTA; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; PLASMA CELLS; RECEPTORS, IMMUNOLOGIC; SYNOVIAL MEMBRANE;

EID: 84888815882     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4400     Document Type: Article

References (39)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219. 10.1056/NEJMra1004965, 22150039.
2. Vander Cruyssen B, Peene I, Cantaert T, Hoffman IE, De Rycke L, Veys EM, De Keyser F. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 2005, 4:468-474. 10.1016/j.autrev.2005.04.018, 16137613.
3. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123. 10.1056/NEJMoa050524, 16162882.
4. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 10.1056/NEJMoa032534, 15201414.
5. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004, 20:517-527. 10.1016/S1074-7613(04)00112-8, 15142521.
6. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006, 5:564-576. 10.1038/nrd2085, 16816838.
7. Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 2011, 3:101ra192.
8. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, Bollore K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, Hose D, Fest T, Tarte K, Klein B. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol 2011, 187:3931-3941. 10.4049/jimmunol.1101230, 21918187.
9. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008, 14:2775-2784. 10.1158/1078-0432.CCR-07-4246, 18451245.
10. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 2011, 29:665-705. 10.1146/annurev-immunol-030409-101302, 21219180.
11. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001, 167:5517-5521.
12. Tassi I, Colonna M. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol 2005, 175:7996-8002.
13. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 2002, 39:1-8. 10.1016/S0161-5890(02)00094-9, 12213321.
14. Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol 2009, 10:297-305. 10.1038/ni.1693, 19151721.
15. Lee JK, Boles KS, Mathew PA. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol 2004, 34:2791-2799. 10.1002/eji.200424917, 15368295.
16. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112:1329-1337. 10.1182/blood-2007-08-107292, 2515112, 17906076.
17. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol 2010, 160:348-358. 10.1111/j.1365-2249.2010.04116.x, 2883105, 20345977.
18. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989, 86:10029-10033. 10.1073/pnas.86.24.10029, 298637, 2513570.
19. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006, 176:346-356.
20. Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 1997, 159:3613-3621.
21. Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991, 51:1190-1196. 10.1097/00007890-199106000-00009, 1646504.
22. Bakker NP, Van Erck MG, Otting N, Lardy NM, Noort RC, 't Hart BA, Jonker M, Bontrop RE. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med 1992, 175:933-937. 10.1084/jem.175.4.933, 2119185, 1552289.
23. Otting N, Heijmans CM, Noort RC, de Groot NG, Doxiadis GG, van Rood JJ, Watkins DI, Bontrop RE. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci USA 2005, 102:1626-1631. 10.1073/pnas.0409084102, 545086, 15665097.
24. Hart BA, Bank RA, De Roos JA, Brok H, Jonker M, Theuns HM, Hakimi J, Te Koppele JM. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol 1998, 37:314-323. 10.1093/rheumatology/37.3.314, 9566674.
25. Vierboom MP, Jonker M, Bontrop RE, 't Hart B. Modeling human arthritic diseases in nonhuman primates. Arthritis Res Ther 2005, 7:145-154. 10.1186/ar1773, 1175046, 15987497.
26. Vierboom MP, Jonker M, Tak PP, 't Hart BA. Preclinical models of arthritic disease in non-human primates. Drug Discov Today 2007, 12:327-335. 10.1016/j.drudis.2007.02.012, 17395093.
27. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 1988, 169:197-203. 10.1016/0003-2697(88)90274-6, 3369682.
28. Bakker NP, van Erck MG, Botman CA, Jonker M, 't Hart BA. Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 1991, 34:616-624. 10.1002/art.1780340514, 2025313.
29. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699. 10.1016/S0002-9440(10)63016-7, 1867076, 11696430.
30. De Salort J, Sintes J, Llinas L, Matesanz-Isabel J, Engel P. Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells. Immunol Lett 2011, 134:129-136. 10.1016/j.imlet.2010.09.021, 20933013.
31. Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol 2007, 179:4672-4678.
32. Llinas L, Lazaro A, de Salort J, Matesanz-Isabel J, Sintes J, Engel P. Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol Lett 2011, 134:113-121. 10.1016/j.imlet.2010.10.009, 20951740.
33. Murphy JJ, Hobby P, Vilarino-Varela J, Bishop B, Iordanidou P, Sutton BJ, Norton JD. A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion. Biochem J 2002, 361:431-436. 10.1042/0264-6021:3610431, 1222324, 11802771.
34. Dechanet J, Merville P, Durand I, Banchereau J, Miossec P. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J Clin Invest 1995, 95:456-463. 10.1172/JCI117685, 295488, 7532184.
35. Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, Lebmeier M, Drost P, Bergman G. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 2011, 13:R204. 10.1186/ar3537, 3334657, 22151924.
36. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 2013, 62:1841-1849. 10.1007/s00262-013-1493-8, 24162108.
37. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, Muller PY, Frings W, Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010, 2:233-255. 10.4161/mabs.2.3.11782, 2881251, 20421713.
38. Ding Y, Ju X, Azlan M, Hart DN, Clark GJ. Screening of the HLDA9 panel on peripheral blood dendritic cell populations. Immunol Lett 2011, 134:161-166. 10.1016/j.imlet.2010.10.010, 20970455.
39. Aldhamen YA, Appledorn DM, Seregin SS, Liu CJ, Schuldt NJ, Godbehere S, Amalfitano A. Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens. J Immunol 2011, 186:722-732. 10.4049/jimmunol.1002105, 21149608.